WARRINGTON, Pa., Oct. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled "Capillary System With Fluidic Element." The Company holds a license to this patent (U.S. Patent Application. No. 12/285,312), which will provide additional exclusivity regarding certain proprietary and technical aspects of its capillary aerosol generator (CAG) technology, a key component of its AEROSURF ® program.
Discovery Labs' technology platform includes its synthetic, peptide-containing KL4 surfactant and its proprietary aerosolized drug delivery technologies, including the CAG technology, which has the potential to enable delivery of aerosolized KL4 surfactant without the invasive procedures currently required for surfactant administration. Discovery Labs previously secured worldwide exclusive rights to the CAG technology for use with all pulmonary surfactants, alone or in combination with other pharmaceutical compounds, for a wide range of respiratory disorders. The initial application of the CAG technology is for the Company's AEROSURF development program.
AEROSURF is a novel investigational combination drug-device product being developed to deliver Discovery Labs' KL4 surfactant in aerosolized form to premature infants with respiratory distress syndrome (RDS). AEROSURF could potentially allow for the administration of KL4 surfactant to premature infants without invasive endotracheal intubation, and may enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated. The Company plans to initiate its AEROSURF phase 2 clinical program in the fourth quarter of 2013.
"We are pursuing a broad exclusivities strategy and this patent further enhances a growing list of potential regulatory and patent related exclusivities and provides additional protections for our valuable AEROSURF program," said John G. Cooper, Chief Executive Officer of Discovery Labs.About Discovery Labs Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs' technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV